GenePharm

Executive Summary

GenePharm is a privately held European biotechnology company headquartered in Zurich, Switzerland, with a state-of-the-art 12,000 m² manufacturing facility in Pallini Attica, Greece. Founded in 1998, the company specializes in antibodies, proteomics, and diagnostics, operating two advanced production lines compliant with EU GMP standards. These lines focus on conventional pharmaceuticals and oncological solids, positioning GenePharm as a versatile contract development and manufacturing organization (CDMO) for both generic and specialty drugs. The company's private ownership and lack of disclosed fundraising suggest a steady, self-sustained operation with an established client base. GenePharm's strategic location in Europe provides access to a well-regulated market and a growing demand for oncology and specialty generics. While the company has not publicly disclosed recent pipeline developments or financial details, its long history and modern facilities indicate operational stability. Near-term growth is likely driven by expanding its CDMO services, capitalizing on the rising trend of drug outsourcing, and potentially launching new diagnostic or antibody products. The company's low public profile suggests limited near-term visibility, but its infrastructure and niche focus offer a moderate conviction for steady performance rather than explosive growth.

Upcoming Catalysts (preview)

• Q3 2026Expansion of oncology solid production capacity70% success
• H2 2026Strategic partnership for antibody-based diagnostic kits50% success
• Q4 2026Entry into new European or Asian markets via CDMO contracts65% success